Approximately 70% of breast cancers are positive for estrogen receptor (ER) α at diagnosis, and these patients often benefit from endocrine therapies that target ER, because the proliferative drive of these tumors and many of their phenotypic properties result from estrogens acting through the ER [1]. This evidence concerns the gene ESR1 and breast carcinoma.